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N-acetylcysteine as add-on to
antidepressant medication in therapy
refractory major depressive disorder
patients with increased inflammatory
activity: study protocol of a double-blind
randomized placebo-controlled trial
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Abstract
Background: A subgroup of depressed patients with increased inflammatory activity was shown to be more
susceptible to develop Treatment Resistant Depression (TRD). Earlier studies with anti-inflammatory drugs have
shown benefits in the treatment of major depressive disorder (MDD), but the effects are expected to be higher in
patients with increased inflammatory activity. Supplementation of N-acetylcysteine (NAC) to ongoing antidepressant
therapy may positively influence outcome of depression treatment in these patients. Therefore, this study aims to
investigate the efficacy of NAC supplementation in patients with insufficient response to standard antidepressant
treatment, and to explore potential roles of inflammation and oxidative stress involved in the alleged
pathophysiological processes of TRD.
Methods/design: A double-blind randomized placebo-controlled study comparing NAC versus placebo as add-on
medication to antidepressant treatment with 12-week treatment and 8-week follow up in patients with TRD and
increased inflammatory activity. Apart from clinical efficacy defined as the change in Hamilton Depression Rating
Scale (HAMD)-17 score, secondary outcomes include changes in pathophysiological mechanisms related to
depression as well as changes in local brain activity (functional Magnetic Resonance Imaging, fMRI) and white
matter integrity (Diffusion Tensor Imaging, DTI). Importantly, sole patients with CRP levels with values between 0.85
and 10 mg/L will be included.
Discussion: This is the first clinical trial taking both TRD and increased inflammatory activity as inclusion criteria.
This study will provide reliable evidence for the efficacy of NAC in patients with TRD displaying increased
inflammatory activity. And this study also will help explore further the roles of inflammation and oxidative stress
involved in the alleged pathophysiological processes of TRD.
Trial registration: The trial protocol has been registered on “ClinicalTrials.gov“with protocol ID “NAC-2015-TJAH”
and ClinicalTrials.gov ID “NCT02972398”.
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Background
MDD is a highly recurrent, insidious and heterogeneous
mental disorder. Worldwide the disease burden for both
individuals and society is enormous [1], and although
some progress has been made in the treatment of MDD,
it has been estimated that more than one third of MDD
patients do not respond satisfactorily to the initial and
subsequent antidepressant treatments, including combi-
nations of pharmacotherapy and psychotherapy [1].
Overall, 20–30% of patients with MDD have TRD, which
accounts for a large proportion of the overall costs of
MDD [2]. There is thus an urgent need to develop new
and more effective therapeutic strategies.
Recent research indicates that both inflammatory
processes and oxidative stress are part of the biological
substrate of depression. It has also been suggested that
neuro-inflammation plays a key role in TRD [3, 4]. Indeed,
inflammation markers such as the acute phase protein
CRP, pro-inflammatory cytokines, acute phase proteins
and adhesion molecules are often increased in depressed
patients. Notably, neuro-inflammation has been associated
with structural/functional anomalies in the brain [5] but
also with less propensity to respond to antidepressant
treatment [6]. Furthermore, MDD patients with increased
inflammation are more likely to have a chronic course
despite antidepressant treatment [7]. This has led to the
idea that additional anti-inflammatory treatment might
improve treatment efficacy. A recent meta-analysis by
Kohler et al. [8] indeed suggested that anti-inflammatory
treatment, in particular celecoxib, has an effect on depres-
sive symptoms thus advocating further studies in sub-
groups that could specifically benefit from such treatment.
This is in line with an RCT using the TNFα inhibitor
infliximab, which showed that in particular patients with
increased inflammation had a significantly better response
compared to placebo [9].
The glutathione precursor N-acetylcysteine (NAC) has
been reported to positively interfere with several patho-
physiological processes in MDD, including neuro-in-
flammation, glutamate neuronal activity, neurogenesis
and apoptosis [10]. Preliminary evidence from a limited
number of clinical studies indicates that NAC supple-
mentation may also be beneficial in the treatment of
other mental disorders such as schizophrenia, bipolar
disorder and autism [11]. However, a recent randomized
controlled trial in MDD could not demonstrate a statis-
tically significant overall effect of NAC supplementation
to regular antidepressant treatment at 12-week endpoint
[10]. Yet, a secondary analysis suggested a positive effect
of NAC in patients with more severe depression. In this
study, inflammatory activity was not specifically assessed.
In summary, those studies described above on the
relationship between anti-inflammatory agents and anti-
depressive outcomes have specific strengths and
weaknesses. Especially, no specific trial was conducted
to study the efficacy of anti-inflammatory agents on the
TRD patients with increasing inflammatory activity.
Objectives
Our aim is to investigate antidepressant efficacy and
safety of NAC in patients with TRD, displaying increased
peripheral inflammatory activity and moderate to severe
depression. We will also examine a range of biomarkers
related to potentially important underlying biological
mechanisms such as oxidative stress and inflammatory
activity. Apart from studying the effects of NAC on de-
pression severity, we will also study the effects on brain
functioning (fMRI) and on white matter integrity (DTI).
Methods
Study design
This is a double-blind, randomized, placebo-controlled
antidepressant augmentation trial. All participants are
randomly divided into two groups treated orally with
“antidepressant + NAC” (N = 100) or “antidepressant +
placebo” (N = 100).
Duration
Total study duration: 20 weeks (12-week treatment and
8-week follow up).
Setting
Treatment will be given at the Tianjin Anding Hospital
or at home. fMRI scanning is performed at the Imaging
Center of the Tianjin Huanhu Hospital.
Population (base)
The study population will consist of a sample of 200 pa-
tients with major depressive disorder recruited from the
outpatient and inpatient departments of Tianjin Anding
Hospital. The first 50 participants will be recruited for
the MR scanning.
Inclusion criteria
1. A current episode of MDD diagnosed according to
Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition (DSM-IV-TR) diagnosed with
Structured Clinical Interview for DSM-IV (SCID)
2. Age between 18 and 65 years
3. A total score of 17 items Hamilton Depression
Rating Scale (HAMD-17) ≥ 17
4. A CRP level between 0.85 and 10 mg/L
5. Insufficient response to one or more
antidepressants given for at least 6 weeks and in an
adequate dose during the current episode
6. Stable dose of the current antidepressant drug for
at least 2 weeks prior to initiation of the study
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7. Patients are compliant with treatment according to
the judgement of the treating clinician.
8. Female subjects will be eligible to participate in the
study if they are of non-childbearing potential or of
child-bearing potential and willing to practice ap-
propriate birth control methods during the study.
Clinical patients always get a pregnancy test before
start of treatment.
9. Participant or guardian has to sign informed
consent. The patients’ guardians will sign the
informed consent on behalf of the participants
when the capacity of participants to consent is
compromised.
Exclusion criteria
1. A history of manic episode
2. Use of mood stabilizer
3. Use of antipsychotic medication with more than half
of the maximum dosage suggested in the instruction
4. History of substance abuse or dependence
5. An allergic reaction to NAC or any component of
the preparation
6. Severe somatic diseases that might interfere with
regular antidepressant treatment including
conditions such as kidney and liver failure,
uncontrolled hypertension, cardiovascular,
cerebrovascular and pulmonary disease, thyroid
disease, diabetes, epilepsy and asthma.
7. Use of anti-inflammatory medication for longer
than 7 days in the last 2 months preceding the trial
8. Use of immunosuppressive medication such as oral
steroid hormones
9. History of chronic infection, such as tuberculosis,
AIDS, hepatitis
10. CRP value > 10 mg/L
11. Women in pregnancy or lactation period
Additional exclusion criteria for patients participat-
ing in the MR scanning Participants have to fill out a de-
tailed questionnaire covering safety aspects in relation to
research in a 3 Tesla magnetic field and MRI environ-
ment. These criteria are:
1. MR incompatible implants in the body (such as
cochlear implant, insulin pump, pace maker or
other metal implants)
2. Any risk of having metal particles in the eye, due to
manual work without proper eye protections
3. Tattoos containing red pigments
4. Claustrophobia
5. The refusal to be informed of structural brain
abnormalities that could be detected during the
experiment
Sample size calculation
There are only few data available on effect size and
standard deviations for NAC as an antidepressant, and
power calculations therefore remain speculative.
One RCT gave 1000 mg NAC daily as add-on medica-
tion for TRD in a total of 75 included patients with
bipolar disorder and found a statistically significant
effect on the MADRS (depression severity) and Global
Assessment of Functioning (GAF) outcomes [12]. A sec-
ond RCT has treated 269 MDD patients with 2000 mg
NAC augmentation daily for 12 weeks and found no sta-
tistically significant difference on the primary MADRS
outcome in the whole group. However this study did
show significant effects on the CGI and functional out-
comes in patients with more severe depression who had
an initial MADRS score > 24 (p < 0.03) [10]. In our study
we also focus on patients with more severe depression.
For the power analysis we therefore assumed that in
the placebo group 20% will have a positive outcome and
40% in the intervention group. Setting á at 0.05 and â at
0.80 in a two-tailed independent t-test indicated that a
minimum of 91 patients per group is needed (a total of
182 patients with continuity correction). Considering
10% drop-out, we raised the inclusion to 100 per group,
thus a total of 200 included patients.
Strategy for participant enrolment
Firstly, a well-trained team is involved in the enrolment,
including one senior psychiatrist, two research nurses,
two master students working full time, and 20 psychia-
trists motivated to refer patients for scientific research.
Secondly, by giving a more elaborate explanation of the
study goals, including the pros and cons, to both pa-
tients and their guardians they now better understand
the background and possible relevance of the study. Still,
financial support also assists to this work. Lastly, as
Tianjin Anding hospital is the largest mental health facility
in the north of China, with around 540,000 outpatients
every year and 1300 beds, we are confident to finish the
study on schedule using this adapted procedure.
Study parameter/endpoint
Main study parameter/endpoint
HAMD-17: The primary outcome criterion is the change
in HAMD-17 score between the pre-treatment and the
first post-treatment measurement.
Secondary study parameter/endpoint
1. HAMD-17 at 8 weeks’ follow-up after discontinu-
ation of NAC treatment
2. Beck Anxiety Inventory (BAI)
3. Inventory of Depressive Symptoms - Self-Rated
(IDS-SR)
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4. WHO Disability Assessment Schedule (WHODAS-II)
5. Montreal Cognitive Assessment (MoCA)
6. Neuroimaging: DTI and resting state BOLD in the
anterior cingulate cortex (ACC) before and after
treatment in order to determine the general effect
on fiber integrity projected out from ACC and
brain metabolism in ACC (for details see below).
7. Biomarkers representing different
pathophysiological mechanisms associated with
MDD are assessed in venous blood and morning
urine. All will be correlated with the intervention
category and with primary and secondary
outcomes.
Side effects
Possible side effects will be tabulated based on partici-
pant reports throughout the trial using a Checklist of 52
Somatic Items (CSI) described by Berk et al. [12].
Additional study parameters
The influences of gender, age, medication, body weight,
level of treatment resistance assessed by Dutch Method
for staging Therapy-Resistant-Depression (DM-TRD) on
the study outcome will be investigated.
Randomization, blinding and treatment allocation
Subjects will receive NAC or placebo treatments in a
randomized controlled double-blind design. The investi-
gators, clinicians, and statisticians are blind to treatment
allocation until the data analysis is completed. This is ac-
complished as follows:
The placebo is matched to NAC in shape, smell and
color and capsules are sealed in identical bottles.
The medication is labelled as trial medication and
given a random trial number by the trial pharmacist
from 1 to 200. The list with numbers is stored in a se-
cure place and nobody apart from the trial pharmacist
has access to it until the trial is finished.
1. A second person who is not involved in any aspect
of the trial will perform the randomization
procedure by generating a medication number
based on a list with consecutive trial participants
(also from 1 to 200). Randomization procedure:
participants will be assigned to the experimental
group or control group using a randomized
procedure according to enrolled order. From a table
of random numbers, the patient will obtain a
number.
2. The nature and dose of the primary therapy is
monitored.
3. Participants are interviewed separately and have no
opportunity to share their experiences.
Study procedures
Overview of procedure
Subjects receive care as usual while participating in this
study, except that it is not allowed to change the anti-
depressant medication during the study. Antidepressants
are restricted to selective serotonin reuptake inhibitors
(SSRI) and serotonin and noradrenalin reuptake inhibi-
tors (SNRI) and remain unchanged for at least 2 weeks
before entering the trial (sertraline 50-200 mg/d, paroxe-
tine 10-60 mg/d, citalopram 20-60 mg/d, venlafaxine
75-300 mg/d, duloxetine 30-90 mg/d). Benzodiazepines
(BZD) are allowed to relieve anxiety in the first 2 weeks
of antidepressant treatment and for sleeping problems
during the trial if deemed necessary by the treating
physician. BZD use will be recorded at all assessments
during the trial and follow-up. It is not allowed to pre-
scribe any antipsychotic medication with more than half
of the maximum dosage suggested in instructions or as
a mood stabilizer. The experimental NAC treatment is
an addition to ongoing antidepressant treatment. During
the study, it is not allowed to change medication (apart
from BZD) or to commence ECT. (see Fig. 1).
Scale assessments
All scales mentioned above are used. See Table 1 for
details.
Medication use
A dose finding study in six patients indicated that a
NAC dose of 3000 mg daily caused intolerable stomach
complaints. We therefore decided to use the same dose
as in the Berk study [10]. Accordingly, all participants
receive five NAC (200 mg) capsules twice daily
(2000 mg daily) or matching placebo capsules in the
12-week treatment period, as add-on to the existing
treatment for their major depressive episode. After the
treatment period NAC/placebo is withdrawn, while during
the 8-week follow-up regular treatment is kept the same.
Quality control
All selected scales are established, well validated and re-
liable. Two senior psychiatrists possessing ample experi-
ence with the SCID diagnostic scale will guarantee an
accurate diagnosis and resolve any discrepancies during
the scale rating. Moreover, all the professionals involved
in scale rating have undergone a test on internal
consistency with a kappa value of 0.81.
Monitoring adherence
Concentrations of NAC and its metabolites will only be
measured in blood and urine at the different time points
after the study being completed. It is therefore not pos-
sible to actively monitor adherence during the study in
this way. However, pill counts for adherence are done by
Yang et al. BMC Psychiatry  (2018) 18:279 Page 4 of 11
the pharmacy department, and an independent person
confirms the capsule audit. Furthermore, we are confident
that patients will adhere to the treatment with NAC
through an intensive collaboration with the patients’
guardians as well as a financial encouragement for partici-
pants who complete the study.
Routine recordings
Basic information
Name, gender, age, race.
Physical examination
Height, weight, waist circumference, waist-hip ratio,
BMI, blood pressure, heart rate.
Laboratory examination
Routine test
Blood and urine tests including measurements of hepatic
and renal function, glucose, lipids and electrolytes.
Specific test
Blood (serum) and urine will be collected and stored
after centrifugation at − 80°C. Samples will be used for a
recently developed biomarker panel for depression sup-
plemented with a number of inflammatory markers.
Specific test Blood (serum) and urine will be collected
and stored after centrifugation at − 80°C. Biomarkers in
serum and urine will be measured using commercially ob-
tained ELISAs displaying low cross reactivity. The serum
and urine biomarkers are based on the monoamine, stress,
inflammation and neuroplasticity/neurogenesis hypotheses
Fig. 1 Trial flowchart. Eventually 200 patients will be required to finish the treatment study, being randomly divided into two groups including
Trial arm 1 (antidepressant + NAC, n = 100) and Trial 2 (antidepressant + placebo, n = 100). For the fMRI scanning at baseline (week 0) and the
12th week, 50 patients will be included
Table 1 Scale assessments
Scale 1 HAMD-17 Self-rating scale for depressive symptoms
Scale 2 IDS-SR Self-rated inventory for depressive symptoms
BAI Self-reported inventory for anxious symptoms
CSI A list for somatic items
WHODAS-II To assess functioning
MoCA To assess cognition
Scale 3 DM-TRD To measure treatment resistance
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of MDD supplemented with markers for metabolic
syndrome, oxidative stress, endothelial dysfunction and
magnesium deficiency. A combined biomarker panel has
recently been developed and validated in collaboration
with the University Medical Centre of Groningen (UMCG)
in the Netherlands (UCP). Briefly, in a case control study a
combined serum/urine biomarker panel for MDD with
80% sensitivity and 85% specificity was identified in the
ROC analysis. A number of these biomarkers were repli-
cated in a recent antidepressant augmentation study with
the anti-oxidant curcumin [13]. The biomarkers in blood
and urine are outlined below.
Blood
– Inflammatory: CRP; NGAL; IL6; TNF-α; TNF-α-R2;
IFN-γ; S100a (p11); NF-ĸB; S100b
– Metabolic: insulin; leptin; vit D
– Growth factor: BDNF; VEGF; EGF1
– Stress: cortisol; arginine-vasopressin
– Neuromodulator/neuroplasticity: NPY, substance P
– Oxidative stress: c-GMP; isoprostane; SOD, CAT,
glutathione, NO, MDA2
– Endothelial function: calprotectin; endothelin; zonulin
– Mineral homeostasis: aldosterone; thromboxane;
cAMP
Urine
– Inflammatory: HVEM, LTB4
– Growth factor: EGF
– Stress: cortisol1
– Neuromodulator/neuroplasticity: substance P1, midkine
– Oxidative stress: c-GMP, isoprostane
– Endothelial function: calprotectin
– Mineral homeostasis: aldosterone1; thromboxane1
– Metabolic: leptin
– Miscellaneous: m-hydroxyphenylacetate, formate,
alanine, creatinine, malonate, N-methylnicotinamide
(Note: 1 Those biomarkers were identified to change
in a double blind augmentation study with curcumin by
Lopresti, Maes et al. in Eur Neuropsychopharmacol
25(1): 38–50.)
Lists of time points for examinations/assessments
12-week treatment
Examinations and assessments during treatment include
physical examination, scale assessments, medication use
inventory, and laboratory examinations. All the time
points are depicted in Table 2.
8-week follow-up
Examinations and assessments in follow-up duration
include physical examination, scale assessments, and
laboratory examinations. All the time points are depicted
in Table 3.
Neuroimaging
Patients undergo two MRI scan sessions. The first ses-
sion takes place before the treatment starts while the
second session takes place in week 12, before the study
medication is terminated. During this procedure, partici-
pants will be exposed to a 3 Tesla magnetic field
strength with switching gradient fields, radio waves and
scanner noise.
An anatomical scan will be made to obtain the struc-
tural image necessary for the localization of functional
activation. Patients will only be included in the study
upon agreeing to be informed of any coincidental patho-
logical findings. A statement to that effect must be
signed before entrance into the study.
A functional MRI scan (either ASL or EPI) is recorded
during the resting state, i.e. the subjects do not do any
tasks during this scan. Breathing and heart rate are mea-
sured in order to remove variance that correlates with
these rhythms.
A DTI scan is made with two fMRI tasks to assess
connectivity changes due to the treatment. During the
DTI scans, all using the EPI protocol, two fMRI tasks
will be presented to the subjects.
1. Wall of faces [14]
A group of 32 emotional faces is presented at once to
a subject. Subjects have to decide whether they per-
ceived angrier or happy faces. As a baseline, subjects
have to indicate if there are more males or females. The
array of faces either contains an equal (ambiguous,
16:16) or unequal (unambiguous, 26:6) number of faces
with one emotion/gender vs. the other. The duration of
this task is 15 min.
2. Reward task [15]
We will use a monetary incentive delay task to investi-
gate reward sensitivity in the two patient groups. We
expect that both our groups will initially show aberrant
activation patterns -as reward sensitivity is thought to be
a state marker of anhedonia but that the intervention
group will normalize during the course of the treatment.
The task will be a modified version of the task described
by Pizzagalli et al., [15] who found aberrant neural
responses to both reward anticipation and experience in
depression. Every trial consists of a cue indicating trial
type (gain or neutral condition), target presentation and
feedback. Subjects are told that on incentive trials they
may gain money by pressing the button during target
presentation. On neutral trials, subjects are not required
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to respond. The inter-stimulus-interval will vary to pre-
vent expectancy effects. Cue presentation is known to
elicit reward anticipation and feedback about gains
elicits reward experience. Subjects will receive their
obtained rewards at the end of the session. The order of
feedback will be randomized and not associated with ac-
tual performance to ensure equal pay for all the subjects.
The task will include 90 trials of 10 s each, so the total
duration will be around 15 min.
Data management
All data will be entered online into OpenClinica (https://
www.openclinica.com/). OpenClinica provides trace
management of any adjustments in entered data, which
warrants an effective data monitoring.
Auditing strategy
The sponsor will audit the proceeding of this study.
Frequency and procedure of auditing comply with Good
Clinical Practice (GCP) of China. This action is per-
formed independently from the investigators.
Safety reporting
Adverse events (AES)
Adverse events are defined as any undesirable experi-
ence occurring to a subject during the study, whether or
not considered related to NAC. All adverse events
reported spontaneously by the subject or observed by
the investigator or his staff will be recorded.
Serious adverse events (SAEs)
A serious adverse event is any untoward medical occur-
rence or an effect that at any dose:
1. results in death
2. is life threatening (at the time of the event)
3. will require hospitalization or prolongation of
existing inpatients’ hospitalization.
4. results in persistent or significant disability or
incapacity
Any other important medical event that may not result
in death, be life threatening, or require hospitalization,
may be considered a serious adverse experience when,
based upon appropriate medical judgment, the event
may jeopardize the subject or may require an interven-
tion to prevent one of the outcomes listed above.
Reporting of SAEs
The investigator shall report immediately the SAEs to the
applicant and/or Clinical Research Organization (CRO,
sponsor representative). The patient has to be unblinded
urgently (two persons must be present) and receives emer-
gency treatments. Within 24 h the investigator reports the
SAEs to State Food and Drug Administration (SFDA) of
China by faxing a SAEs form. These events also need to
inform other concerned investigators.
Suspected unexpected serious adverse reactions (SUSARs)
Adverse reactions are all untoward and unintended re-
sponses to an investigational product related to any dose
administered.
Unexpected adverse reactions are SUSARs if the fol-
lowing three conditions are met:
1. the event must be serious.
2. there must be a certain degree of probability that
the event is a harmful and an undesirable reaction
to the medicinal product under investigation,
regardless of the administered dose.
3. the adverse reaction must be unexpected, that is to
say, the nature and severity of the adverse reaction
Table 2 clinical assessment time points
Physical Examination Scale Assessments Medication use inventory Laboratory examinations
Baseline √ Scale 1, Scale 2, Scale 3 √ Routine test, Specific test
Week 2 √ Scale 1
Week 4 √ Scale 1, Scale 2
Week 6 Scale 1
Week 8 √ Scale 1, Scale 2
Week 10 Scale 1
Week 12 √ Scale 1, Scale 2 √ Routine test, Specific test
Week 2 indicates that the time point is at the end of the second week after baseline, while other time points are synchronized in the same way







Week 14 √ Scale 1
Week 16 Scale 1, Scale 2
Week 18 Scale 1
Week 20 √ Scale 1, Scale 2 Routine test,
Specific test
Week 14 indicates that the time point is at the end of the 14th week after
baseline, while other time points are synchronized in the same way
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are not in agreement with the product information
as recorded in: a) summary of Product
Characteristics (SPC) for an authorized medicinal
product; b) investigator’s Brochure for an
unauthorized medicinal product.
Reporting of SUSARs
The procedure is same to the reporting of SAEs.
Unblinding procedure
Regular unblinding will take place after ending the treat-
ment period by the research assistant. Emergency
unblinding may only occur on an individual basis for
safety reasons if the information can help the treatment
of SAEs or SUSARs. For emergency unblinding, enve-
lopes are available at the medication storage room at the
in-patient ward, kept separately from the patches, for
the 24 h unblinding service. In the case of a medical
emergency situation as described below, the sealed enve-
lope can be opened by anyone of the medical team and
the treatment assignment of a participant will be un-
blinded. In case of an emergency unblinding, the reason
and time of unblinding will be documented in the study
files. The decision to unblind is at the discretion of the
local investigator.
Emergency unblinding is indicated in the following
situations only:
1. unblinding is necessary for the subjects’ emergency
treatment at the local investigators discretion
2. unblinding is required by local laws or regulations
(in case of SUSARs)
Withdrawal
Withdrawal of individual subjects
Subjects can leave the study at any time for any reason if
they wish to do so without any consequences. The inves-
tigator can decide to withdraw a subject from the study
for urgent medical reasons. All withdrawals are consid-
ered as drop out and the reasons will be recorded.
Specific criteria for withdrawal
Withdrawal from the study will occur:
1. If participants cease taking their trial medication for
seven consecutive days, stop effective contraception,
or became pregnant.
2. If participants revoke their consent or develop
serious adverse events associated with the study
medication, which could occur either at the request
of the patient or the discretion of the investigator.
3. If participants develop a manic episode.
4. If the antidepressant is modified during the trial –
either by the treating physician or at the initiative
of the patient.
5. If participants use non-steroid anti-inflammatory
drugs (NSAIDs) during the trial for more than 7 days.
6. If participants use anti-oxidative substances in
dosages above 200 μg of selenium/day or 500 IU of
vitamin E/day.
Terminate participation
Reasons to terminate a patient’s participation include:
1. The patient withdraws her/his consent
2. Intolerance to the study drug: if a patient
experiences unacceptable side effects, the patient
may decide, or make a joint decision with the
treating physician, to terminate study participation.
Statistical analysis
Descriptive statistics
The data acquired from questionnaires and the other
non-imaging data are summarised by the mean and
standard deviation in case of normal distributions and
by median and quartile in the case of non-normal
distributions.
For the imaging data we will use Statistical Parametric
Mapping 8 (SPM) (Wellcome Department of Cognitive
Neurology London, UK; http://www.fil.ion.ucl.ac.uk).
Pre-processing will be done on the data including re-
alignment, co-registration, and spatial normalisation into
a standard space and smoothing. Statistical analysis will be
based on a voxel-by-voxel multiple regression analysis of
the time-courses. First level analyses will be done using
GLM. For the second level, random effects analysis will be
conducted. Contrasts in a second level analysis will be
made between the four study groups. Furthermore, corre-
lations will be calculated between brain activation in a
region of interest and questionnaire scores.
Analysis of treatment effect
The effect of treatment (placebo/NAC) is investigated
on the HAMD-17 by comparing differences between
both groups in change of severity scores between base-
line and endpoint (12th). And we also compare differ-
ences between the baseline and other time points (2nd,
4th, 6th, 8th and 10th) and for 8 weeks follow-up (until
week 20). Linear mixed models are used because these
models have the advantage of using all available data.
We will use models with treatment group, time since
intervention (as a categorical variable with two levels),
and the interaction between time and treatment group,
with pre-treatment scores as covariates. In this model, a
significant main effect for treatment group indicates an
overall treatment effect over the entire study period. The
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interaction term is added to assess the effect at the dif-
ferent time points (post-treatment and follow up).
Moderation of treatment effect
To investigate the potential moderating effects of other
factors (e.g. age, gender), two separate ANCOVAs will
be used to investigate whether treatment differences at
post-treatment and/or at follow up are moderated by
gender, age, or treatment expectancy. To this end, the
treatment variable (placebo/NAC), the potential moder-
ator, and their interaction will be included in the model.
Pre-treatment values are used as a covariate to correct
for possible differences in baseline values. Each potential
moderator will be tested in a separate model.
Discussion
A recent clinical study has shown beneficial effects of
anti-inflammatory co-medication with antidepressants in
depressed patients with increased levels of peripheral
inflammation [16]. This is in line with a study by Raison
et al. [9] who performed a proof-of-concept study with a
TNF antagonist in patients with TRD and showed im-
provement in patients with high baseline inflammatory
biomarkers. These studies provided the rationale to
design the current randomized controlled trial with the
anti-inflammatory agent N-acetylcysteine in TRD pa-
tients with increased inflammatory activity. Although an
earlier study by Berk et al. failed to demonstrate overall
significant beneficial effects of NAC supplementation to
regular antidepressant treatment at 12-week end point
[10], a secondary analysis suggested a positive effect of
NAC in patients with more severe depression. In con-
trast to the present study inflammatory activity was not
specifically assessed in the study by Berk et al. [10] but
work from our own group has shown that increased
inflammatory activity is related to non-response in
depressed patients treated with antidepressants [7]. By
sharpening the inclusion criteria in the present study, we
expect to reduce heterogeneity of the patient sample,
diminish possible confounding effects by other medica-
tions and develop a tailored intervention for patients
with mood disorder with inflammatory dysregulation
who have do not respond to regular phases of anti-
depressant treatment. To this end, solely participants
with relatively higher CRP levels with values between
0.85 and 10 mg/L will be included, representing around
one third of all MDD patients who are treated in our
hospital. In addition, patients are selected on basis of
treatment resistance defined as an insufficient response
to 1 or more antidepressants given for at least 6 weeks
in an adequate dose during the current episode. More-
over, restrictions will be made with respect to additional
medication use, such as benzodiazepines, anti-inflammatory
agents and antidepressant medications with anti-
inflammatory properties. With these measures we strive to
select a more homogenous subgroup of MDD patients for
whom NAC may indeed provide an effective adjuvant treat-
ment strategy to reduce their depressive symptoms. MDD
has been associated with functional brain abnormalities
including aberrant brain activity and abnormal functional
connectivity between brain areas [17, 18]. Yet, functional
imaging and peripheral biomarker measurements in
patients with TRD are relatively scarce. By introducing such
measurements in the present study we hope to provide
additional information regarding the pathophysiological
processes involved in TRD including their relation with
treatment response [19]. Conversely such information may
be useful to verify or falsify our working hypothesis that
inflammatory processes and oxidative stress play a pivotal
role in this TRD sample.
There are some limitations of this design. Firstly, there
is still lack of consensus on the definition of TRD. For
instance, depression severity in patients who do not
sufficiently respond to 1 antidepressant treatment and
patients not sufficiently responding to more than 1 anti-
depressant treatment may be significantly different,
potentially causing a dysbalance between these groups.
Similarly, our protocol does not take duration of the
current episode into account, which may also be an
aspect of treatment resistance [20, 21]. Secondly, puta-
tive confounding factors such as frequency of episodes,
family history, and personality traits are not represented
in the inclusion criteria. Thirdly, we choose a dose of
2000 mg NAC based on the results of earlier studies [10,
11], but it may be that a higher dosage is more effective.
One study in ADHD showed beneficial effects with a
dosage of 4800 mg [22]. However, decreased tolerability
of this higher dose was clearly shown in our pilot study
using 3000 mg. It should be noted that earlier studies
with NAC in psychiatry were performed in Australian
patient populations. Arguably Chinese people may be
more sensitive to NAC administration as might be
concluded by the beneficial effects of relatively lower
dosages in chronic obstructive pulmonary disease (COPD)
compared with Caucasians [23–25]. In addition, we now
focus specifically on a TRD patient group with increased
inflammatory activity which potentially may show a better
response to treatment with an anti-inflammatory agent.
Finally, the treatment duration we chose in our study is
similar to that of previous studies [10] in which effects
were found in the follow-up period but not at the end of
treatment. For this reason, we prolonged the follow-up
duration to 20 weeks. It is, however, conceivable that treat-
ment for a longer period of time would yield better results.
In conclusion, despite these limitations, this study is
expected to provide reliable evidence for the efficacy of
NAC in patients with TRD displaying increased inflam-
matory activity.
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